Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT02 in advanced solid tumors
NCT06404905Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BT02 in solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events at 28 days and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
BT02
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06404905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06404905.